Simultaneous Evaluation of Dissolution and Permeation of Oral Drug Solid Formulations for Predicting Absorption Rate–Limiting Factors and In Vitro–In Vivo Correlations: Case Study Using a Poorly Soluble Weakly Basic Drug
Combined dissolution and permeation systems are designed to simultaneously assess the dissolution of a pharmaceutical dosage form and the permeation of dissolved drugs therefrom. However, there were still some limitations on predicting the possible absorption rate–limiting steps and improving the in vitro–in vivo correlation (IVIVC) of a complete dosage form. In this study, the modified biorelevant media with some solubilizers and pH modifiers were integrated into the drug dissolution/absorption simulating system (DDASS). Indapamide, a poorly soluble compound (pKa = 8.8), was selected to validate the applicability of the modified biorelevant media. The elution and permeation dynamics of indapamide were investigated by using appropriate solubilizing agents in the DDASS. The absorption behaviors were analyzed after oral administration of indapamide in beagle dogs. The absorption rate–limiting steps and IVIVCs were predicted from the dissolution–permeation–absorption dynamic parameters. As a result, the absorption fraction of indapamide in the FaSSIFmod of DDASS was estimated to be approximately 100%, in accordance with its high permeability. The ratios of permeation rate to elution rate were 2.55 and 3.34 for the immediate- and sustained-release tablets of indapamide, respectively, suggesting a dissolution rate–limiting absorption for indapamine. In addition, point-to-point correlations were established between in vitro elution and in vivo absorption by the nonlinear and linear regression analysis ways (r > 0.85). The findings indicate that DDASS is a promising technique to develop improved IVIVCs of a complete dosage form, and the FaSSIFmod is suitable to predict the possible absorption rate–limiting steps of poorly soluble drugs in DDASS.
KEY WORDSpoorly water-soluble drugs in vitro–in vivo correlation indapamide pharmacokinetic drug dissolution/absorption simulating system
This work was supported by grants from the Key Support Projects of Tianjin Science and Technology (16YFZCSY00440), Changjiang Scholars and Innovative Research Team (IRT_14R41), and Tianjin Natural Science Foundation (18JCQNJC83800).
Compliance with ethical standards
This study protocol was approved by the Ethical Review Committee of Second Affiliated Hospital of Tianjin University of TCM. The animal experiments were performed in accordance with the Principles of Laboratory Animal Care (NIH No. 8523).
Conflict of interest
The authors declare that they have no conflict of interest.
- 4.Borbás E, Nagy ZK, Nagy B, Balogh A, Farkas B, Tsinman O, et al. The effect of formulation additives on in vitro dissolution-absorption profile and in vivo bioavailability of telmisartan from brand and generic formulations. Eur J Pharm Sci. 2018;114:310–7. https://doi.org/10.1016/j.ejps.2017.12.029.CrossRefPubMedGoogle Scholar
- 7.Beig A, Fine-Shamir N, Lindley D, Miller JM, Dahan A. Advantageous solubility-permeability interplay when using amorphous solid dispersion (ASD) formulation for the BCS class IV P-gp substrate rifaximin: simultaneous increase of both the solubility and the permeability. AAPS J. 2017;19:806–13. https://doi.org/10.1208/s12248-017-0052-1.CrossRefPubMedGoogle Scholar
- 9.Kobayashi M, Sada N, Sugawara M, Iseki K, Miyazaki K. Development of a new system for prediction of drug absorption that takes into account drug dissolution and pH change in the gastro-intestinal tract. Int J Pharm. 2001;221:87–94. https://doi.org/10.1016/S0378-5173(01)00663-9.CrossRefPubMedGoogle Scholar
- 10.Kataoka M, Masaoka Y, Yamazaki Y, Sakane T, Sezaki H, Yamashita S. In vitro system to evaluate oral absorption of poorly water-soluble drugs: simultaneous analysis on dissolution and permeation of drugs. Pharm Res. 2003;20:1674–80. https://doi.org/10.1023/A:1026107906191.CrossRefPubMedGoogle Scholar
- 11.Motz SA, Schaefer UF, Balbach S, Eichinger T, Lehr CM. Permeability assessment for solid oral drug formulations based on Caco-2 monolayer in combination with a flow through dissolution cell. Eur J Pharm Biopharm. 2007;66:286–95. https://doi.org/10.1016/j.ejpb.2006.10.015.CrossRefPubMedGoogle Scholar
- 16.Li ZQ, Tian S, Gu H, Wu ZG, Nyagblordzro M, Feng G, et al. In vitro-in vivo predictive dissolution-permeation-absorption dynamics of highly permeable drug extended-release tablets via drug dissolution/absorption simulating system and pH alteration. AAPS PharmSciTech. 2018;19:1–12. https://doi.org/10.1208/s12249-018-0996-1.CrossRefGoogle Scholar
- 29.Kataoka M, Fukahori M, Ikemura A, Kubota A, Higashino H, Sakuma S, et al. Effects of gastric ph on oral drug absorption: in vitro assessment using a dissolution/permeation system reflecting the gastric dissolution process. Eur J Pharm Biopharm. 2016;101:103–11. https://doi.org/10.1016/j.ejpb.2016.02.002.CrossRefPubMedGoogle Scholar
- 30.Mizoguchi M, Kataoka M, Yokoyama K, Aihara R, Wada K, Yamashita S. Application of an in vitro dissolution/permeation system to early screening of oral formulations of poorly soluble, weakly basic drugs containing an acidic pH-modifier. J Pharm Sci. 2018;107:2404–10. https://doi.org/10.1016/j.xphs.2018.05.009.CrossRefPubMedGoogle Scholar
- 32.Kristin F, Carl R, David D, Filippos K, Moritz AK, Johanna M, et al. Optimization of the Ussing chamber setup with excised rat intestinal segments for dissolution/permeation experiments of poorly soluble drugs. Drug Dev Ind Pharm. 2017;43:338–46. https://doi.org/10.1080/03639045.2016.1251449.CrossRefGoogle Scholar
- 36.Song W, Cun D, Quan P, Liu N, Chen Y, Cui H, et al. Dual-directional regulation of drug permeating amount by combining the technique of ion-pair complexation with chemical enhancers for the synchronous permeation of indapamide and bisoprolol in their compound patch through rabbit skin. Eur J Pharm Biopharm. 2015;91:59–65. https://doi.org/10.1016/j.ejpb.2015.01.025.CrossRefPubMedGoogle Scholar
- 39.Cuine A, De Barochez BH, Guez D. Matrix tablet permitting the sustained release of indapamide after oral administration: U.S. Patent 5,334,392[P]. 1994-8-2.Google Scholar
- 40.Aungst BJ. Intestinal permeation enhancers. J Pharm Sci. 2000;89(4):429–42. https://doi.org/10.1002/(SICI)1520-6017(200004)89:4<429::AID-JPS1>3.0.CO;2-J.CrossRefGoogle Scholar
- 46.Lind ML, Jacobsen J, Holm R, Müllertz A. Development of simulated intestinal fluids containing nutrients as transport media in the Caco-2 cell culture model: assessment of cell viability, monolayer integrity and transport of a poorly aqueous soluble drug and a substrate of efflux mechanisms. Eur J Pharm Sci. 2007;32(4-5):261–70. https://doi.org/10.1016/j.ejps.2007.08.002.CrossRefPubMedGoogle Scholar
- 48.Schiavi P, Jochemsen R, Guez D. Pharmacokinetics of sustained and immediate release formulations of indapamide after single and repeated oral administration in healthy volunteers. Fund Clin Pharmacol. 2010;14:139–46. https://doi.org/10.1111/j.1472-8206.2000.tb00402.x.CrossRefGoogle Scholar
- 52.Ayman E-K, Hurst S, Brodfuehrer J, Cho-Ming L. Anatomical and physiological factors affecting oral drug bioavailability in rats, dogs, and humans. In: Oral bioavailability: basic principles, advanced concepts, and applications. Hoboken: John Wiley & Sons, Inc; 2011.Google Scholar